A5032680571- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Immune responses and vaccinations
- Immunodeficiency and Autoimmune Disorders
- Tuberculosis Research and Epidemiology
- vaccines and immunoinformatics approaches
- Biosensors and Analytical Detection
- Monoclonal and Polyclonal Antibodies Research
- Animal Virus Infections Studies
- Cytomegalovirus and herpesvirus research
- COVID-19 Impact on Reproduction
- Advanced Biosensing Techniques and Applications
- Viral Infections and Outbreaks Research
- Viral Infections and Immunology Research
- Virus-based gene therapy research
- Drug-Induced Adverse Reactions
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- COVID-19 diagnosis using AI
- Infective Endocarditis Diagnosis and Management
- Viral Infections and Vectors
- Long-Term Effects of COVID-19
- Thermal Regulation in Medicine
- Acupuncture Treatment Research Studies
Huazhong University of Science and Technology
2020-2024
To fully decipher the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein, it is essential to assess which part highly immunogenic in a systematic way. We generate linear epitope landscape protein by analyzing serum immunoglobulin G (IgG) response 1,051 disease 2019 (COVID-19) patients with peptide microarray. reveal two regions rich epitopes, i.e., C-terminal domain (CTD) and region close S2′ cleavage site fusion peptide. Unexpectedly, we find that...
Abstract Background The missing asymptomatic COVID‐19 infections have been overlooked because of the imperfect sensitivity nucleic acid testing (NAT). Globally understanding humoral immunity in carriers will provide scientific knowledge for developing serological tests, improving early identification, and implementing more rational control strategies against pandemic. Measure Utilizing both NAT commercial kits serum IgM IgG antibodies, we extensively screened 11 766 epidemiologically...
Abstract Serological tests play an essential role in monitoring and combating the COVID-19 pandemic. Recombinant spike protein (S protein), especially S1 protein, is one of major reagents used for serological tests. However, high cost S production possible cross-reactivity with other human coronaviruses pose unavoidable challenges. By taking advantage a peptide microarray full coverage, we analyzed 2,434 sera from 858 patients, 63 asymptomatic patients 610 controls collected multiple...
The immunogenicity of the SARS-CoV-2 proteome is largely unknown, especially for non-structural proteins and accessory proteins. In this study, we collect 2,360 COVID-19 sera 601 control sera. We analyze these on a protein microarray with 20 SARS-CoV-2, building an antibody response landscape immunoglobulin (Ig)G IgM. Non-structural NSP1, NSP7, NSP8, RdRp, ORF3b, ORF9b elicit prevalent IgG responses. patterns dynamics non-structural/accessory are different from those S N responses against...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants of concern (VOCs) have prolonged disease 2019 (COVID‐19) pandemic by escaping pre‐existing immunity acquired natural infection or vaccination. Elucidation VOCs' mutation trends and evasion neutralization is required to update current control measures. Mutations the prevalence VOCs were analyzed in global immunization coverage rate context. Lentivirus‐based pseudovirus analysis platforms for SARS‐CoV‐2 prototype...
The Bacillus Calmette-Guérin (BCG) vaccine, currently the sole authorized vaccine against tuberculosis (TB), demonstrates limited effectiveness in safeguarding adolescents and adults from active TB, even when administered as a booster with either BCG itself or heterologous candidates. To effectively control persistent epidemic of adult it is imperative to investigate mechanisms responsible for suboptimal efficacy prime-boosting strategy primary Mycobacterium (M.tb) infection. C57BL/6J mice...
Abstract Neutralization antibodies and vaccines for treating COVID-19 are desperately needed. For precise development of vaccines, the key is to understand which part SARS-CoV-2 Spike protein highly immunogenic on a systematic way. We generate linear epitope landscape by analyzing serum IgG response 1,051 patients with peptide microarray. reveal two regions that rich epitopes, i.e ., CTD region close S2’ cleavage site fusion peptide. Unexpectedly, we find RBD lack epitope. Besides 3 moderate...
The COVID-19 global pandemic is far from ending. There an urgent need to identify applicable biomarkers for early predicting the outcome of COVID-19. Growing evidences have revealed that SARS-CoV-2 specific antibodies evolved with disease progression and severity in COIVD-19 patients.We assumed may serve as clinical hospitalized patients on admission.By taking advantage a newly developed proteome microarray, we surveyed IgG responses against 20 proteins 1034 admission followed till 66 days....
Abstract Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection recovery from COVID-19. However, differences immune responses clinical features COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM parameters (named COVID-ONE-hi). COVID-ONE-hi based on the data that contain 24 full-length/truncated...
Abstract Importance Asymptomatic COVID-19 infections have a long duration of viral shedding and contribute substantially to disease transmission. However, the missing asymptomatic cases been significantly overlooked because imperfect sensitivity nucleic acid testing. We aimed investigate humoral immunity in asymptomatics, which will help us develop serological tests improve early identification, understand COVID-19, provide more rational control strategies for pandemic. Objective To better...
Neutralization antibodies and vaccines for treating COVID-19 are desperately needed. For precise development of vaccines, the key is to understand which part SARS-CoV-2 Spike protein highly immunogenic on a systematic way. We generate linear epitope landscape by analyzing serum IgG response 1,051 patients with peptide microarray. reveal two regions that rich epitopes, i.e., CTD region close S2' cleavage site fusion peptide. Unexpectedly, we find RBD lack epitope. Besides 3 moderate peptides...
Mycobacterium bovis bacillus Calmette-Guérin (BCG) is an attenuated live vaccine that provides insufficient protection against tuberculosis (TB), the underlying mechanisms for which remain unknown. Assuming BCG inherits immune evasive strategies from virulent parent M. strains, we aimed to identify associated genes and assess their effects on efficacy.Three genes, BCG_3174, BCG_1782, BCG_2432c, with evasion were first identified via bioinformatics analysis then confirmed in genome of 12...
Background. Neutralizing antibody (nAb) response is generated following infection or immunization and plays an important role in the protection against a broad of viral infections. The nAb during clinical progression coronavirus disease 2019 (COVID-19) remains little known. Methods. 123 COVID-19 patients hospitalization Tongji Hospital were involved this retrospective study. grouped based on severity outcome. responses 194 serum samples collected from these within investigation period 60...
<title>Abstract</title> <bold>Introduction</bold>: The only authorized tuberculosis (TB) vaccine, Bacillus Calmette-Guérin (BCG), has shown limited effectiveness in protecting adolescents and adults against active TB, even boosted with either BCG itself or heterologous vaccine candidates. <bold>Objectives</bold>: mechanisms underlying the suboptimal efficacy of revaccination primary <italic>M.tb</italic> infection remain unknown. <bold>Methods</bold>: C57BL/6J mice were immunized once twice,...
Background: The COIVD-19 global pandemic is far from ending. There an urgent need to identify applicable biomarkers for predicting the outcome of COVID-19. Growing evidences have revealed that SARS-CoV-2 specific antibodies remain elevated with disease progression and severity in patients. We assumed may serve as outcome.Method: By taking advantage a newly developed proteome microarray, we surveyed IgM/IgG responses against 20 proteins 1,034 hospitalized COVID-19 patients on admission, who...
Abstract Serological test plays an essential role in monitoring and combating COVID-19 pandemic. Recombinant spike protein (S protein), especially S1 is one of the major reagents for serological tests. However, high cost production S protein, possible cross-reactivity with other human coronaviruses poses unneglectable challenges. Taking advantage a peptide microarray full coverage, we analyzed 2,434 sera from 858 patients, 63 asymptomatic patients 610 controls collected multiple clinical...
Abstract The COVID-19 global pandemic is far from ending. There an urgent need to identify applicable biomarkers for early predicting the outcome of COVID-19. Growing evidences have revealed that SARS-CoV-2 specific antibodies evolved with disease progression and severity in COIVD-19 patients. We assumed may serve as outcome. By taking advantage a newly developed proteome microarray, we surveyed IgG responses against 20 proteins 1,034 hospitalized patients on admission followed till 66 days....
Summary The immunogenicity of SARS-CoV-2 proteome is largely unknown, especially for non-structural proteins and accessory proteins. Here we collected 2,360 COVID-19 sera 601 control sera. We analyzed these on a protein microarray with 20 SARS-CoV-2, built an antibody response landscape IgG IgM. found that NSP1, NSP7, NSP8, RdRp, ORF3b ORF9b elicit prevalent responses. patterns dynamic non-structural/ are different from S N protein. responses against 6 associated disease severity clinical...
Abstract Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection recovery from COVID-19. However, differences immune responses clinical features COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM parameters (COVID-ONE humoral immune). COVID-ONE based on dataset that contains the 21 of 28 known proteins...
The immunogenicity of SARS-CoV-2 proteome is largely unknown, especially for non-structural proteins and accessory proteins. Here we collected 2,360 COVID-19 sera 601 control sera. We analyzed these on a protein microarray with 20 SARS-CoV-2, built an antibody response landscape IgG IgM. found that NSP1, NSP7, NSP8, RdRp, ORF3b ORF9b elicit prevalent responses. patterns dynamic non-structural/ are different from S N protein. responses against 6 associated disease severity clinical outcome...